Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pain Relief Investigation of NeuroModulation Therapy in Adult Humans

This study has been terminated.
Sponsor:
Collaborator:
PharmaNet
Information provided by:
Fralex Therapeutics
ClinicalTrials.gov Identifier:
NCT00253032
First received: November 11, 2005
Last updated: March 2, 2006
Last verified: March 2006
  Purpose
The study is being performed to determine the efficacy and safety of Fralex Neuromodulation Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal pain.

Condition Intervention Phase
Chronic Musculoskeletal Pain
Device: PRIMA
Phase 3

Study Type: Interventional
Official Title: PRIMA Study: Pain Relief Investigation of NeuroModulation Therapy in an Adult Population: A Double Blind, Randomized, Multicenter, Placebo Controlled Trial.

Further study details as provided by Fralex Therapeutics:

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

ClinicalTrials.gov Identifier: NCT00253032     History of Changes
Other Study ID Numbers: F05001 
Study First Received: November 11, 2005
Last Updated: March 2, 2006
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Additional relevant MeSH terms:
Musculoskeletal Pain
Muscular Diseases
Musculoskeletal Diseases
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on December 07, 2016